Sangamo Therapeutics, Inc.
NASDAQ:SGMO · NASDAQ Global Select
+$0.00 today
Vol 0.51M · Avg 9.53M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $27.6M |
| Receivables | $6.4M |
| Other Current | $3.2M |
| Total Current Assets | $37.1M |
| PP&E (Net) | $13.2M |
| Other Non-current | $9.6M |
| Total Non-current Assets | $22.9M |
| Total Assets | $60.0M |
Analysis
Selected assets total $60.0M for Latest. The largest visible component is Cash & Equivalents at $27.6M, about 46.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.9M -50.0% | $41.9M -7.3% | $45.2M -55.0% | $100.4M -43.8% | $178.9M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 -100.0% | $35.8M -79.8% | $177.2M -10.4% | $197.7M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $10.5M +128.6% | $4.6M +13.1% | $4.1M -9.1% | $4.5M -29.7% | $6.4M | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $4.4M -15.6% | $5.2M -44.1% | $9.3M | $0 | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $35.8M -30.7% | $51.7M -45.2% | $94.3M -68.6% | $300.3M -24.7% | $398.8M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $14.1M -59.4% | $34.8M -34.3% | $52.9M -57.9% | $125.5M +0.7% | $124.7M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 -100.0% | $37.6M -5.4% | $39.7M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 -100.0% | $50.7M -5.6% | $53.8M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 -100.0% | $1.5M +0.0% | $1.5M -95.0% | $29.8M -66.2% | $88.2M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 -100.0% | $6.3M | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $9.8M -28.3% | $13.7M -17.7% | $16.6M +35.7% | $12.3M -27.1% | $16.8M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $23.9M -52.1% | $49.9M -29.6% | $71.0M -72.9% | $262.2M -18.9% | $323.2M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $59.7M -41.2% | $101.6M -38.5% | $165.3M -70.6% | $562.5M -22.1% | $721.9M | $13.3B | $11.9B | $10.6B |
| Account Payables | $14.4M -6.8% | $15.5M +1.5% | $15.3M -31.9% | $22.4M +129.7% | $9.8M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $10.1M +149.1% | $4.1M | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $899.0K -88.1% | $7.6M | $0 -100.0% | $51.8M -39.6% | $85.7M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $17.7M +21.6% | $14.6M +24.2% | $11.7M -1.3% | $11.9M -43.0% | $20.8M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $42.5M -7.3% | $45.8M -4.0% | $47.7M -57.3% | $111.7M -12.6% | $127.9M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 -100.0% | $6.3M -5.6% | $6.6M | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $5.9M +0.0% | $5.9M | $0 -100.0% | $109.4M -34.4% | $166.8M | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $580.0K -37.8% | $933.0K -21.4% | $1.2M -1.7% | $1.2M -0.8% | $1.2M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $31.5M -4.6% | $33.1M -4.7% | $34.7M -77.7% | $155.8M -28.7% | $218.7M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $74.0M -6.2% | $78.9M -4.3% | $82.4M -69.2% | $267.6M -22.8% | $346.6M | $14.7B | $3.7B | $9.6B |
| Common Stock | $3.5M +64.8% | $2.1M +19.5% | $1.8M +6.8% | $1.7M +14.3% | $1.5M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$1.6B -8.2% | -$1.5B -7.0% | -$1.4B -22.4% | -$1.1B -20.1% | -$956.3M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$1.5M +80.6% | -$7.5M -63.9% | -$4.6M +45.3% | -$8.4M -110.8% | -$4.0M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | -$14.3M -162.7% | $22.8M -72.5% | $82.9M -71.9% | $295.0M -21.4% | $375.3M | $9.1B | $7.7B | $3.3B |
| Total Debt | $26.8M -12.3% | $30.6M -19.8% | $38.1M -11.6% | $43.1M -10.3% | $48.1M | $724.2M | $410.6M | $399.4M |
| Net Debt | $5.8M +151.5% | -$11.4M -59.9% | -$7.1M +87.6% | -$57.3M +56.2% | -$130.8M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
C4 Therapeutics, Inc.
NASDAQ:CCCC
$335.86M
OmniAb, Inc.
NASDAQ:OABI
$264.31M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$254.77M
Codexis, Inc.
NASDAQ:CDXS
$233.15M
Innate Pharma S.A.
NASDAQ:IPHA
$171.37M
Molecular Partners AG
NASDAQ:MOLN
$147.61M
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
$144.94M
Invivyd, Inc.
NASDAQ:IVVD
$126.86M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$113.80M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$50.69M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does SGMO have?
Sangamo Therapeutics, Inc. (SGMO) reported $20.95M in cash and equivalents in fiscal 2025.
How much debt does SGMO carry?
Sangamo Therapeutics, Inc. (SGMO) reported $26.80M of total debt, with net debt of $5.85M.
Explore More
Continue the stock analysis
Jump to another research area for this company.